Ya Zheng, Zhaofeng Chen, Xiangyi Zan, Xidong Fang, Feifei Chen, Qian Ren, Yuping Wang, Qinghong Guo, Rui Ji, Yongning Zhou
{"title":"血清TFF2作为胃癌和早期胃癌更可靠的生物标志物：一项基于人群的横断面研究","authors":"Ya Zheng, Zhaofeng Chen, Xiangyi Zan, Xidong Fang, Feifei Chen, Qian Ren, Yuping Wang, Qinghong Guo, Rui Ji, Yongning Zhou","doi":"10.1007/s10120-025-01644-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>TFF2 is a promising yet underexplored biomarker for gastric cancer. We aimed to investigate the relationship between serum TFF2 and gastric cancer, including early gastric cancer, and its interactions with other factors.</p><p><strong>Methods: </strong>A cross-sectional, population-based study was conducted involving 3986 participants from Wuwei Cohort. The serum levels of TFF2, TFF1, TFF3, PG I, PG II, and Hp IgG were measured. Logistic regression and restricted cubic splines assessed associations and dose-response relationships.</p><p><strong>Results: </strong>Gastric cancer prevalence rose across serum TFF2 tertiles, from 1.6 to 5.0% (p for trend < 0.001). TFF2 demonstrated the strongest association with gastric cancer, with participants in the highest tertile showing over a fourfold increased risk (OR 4.02, 95% CI 2.25-7.19, p < 0.001) after adjusting for traditional risk factors and other biomarkers. The association remained robust for early gastric cancer, exhibiting over a threefold risk (OR 3.31, 95% CI 1.80-6.08, p < 0.001). RCS analyses confirmed dose-response relationships (p for non-linearity < 0.05). The joint analyses showed that participants in the highest tertiles of both TFF1 and TFF2, or in the lowest tertile of TFF1 and highest tertile of TFF2, had at least an eightfold increased risk of gastric cancer and early gastric cancer compared to those with both biomarkers in the lowest tertile.</p><p><strong>Conclusion: </strong>Serum TFF2 is a more reliable biomarker for gastric cancer, including early gastric cancer, in the general population. Its strong dose-response association with gastric cancer outcomes and the synergistic effects with TFF1 highlight its potential to improve risk prediction and guide future research.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"852-861"},"PeriodicalIF":5.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study.\",\"authors\":\"Ya Zheng, Zhaofeng Chen, Xiangyi Zan, Xidong Fang, Feifei Chen, Qian Ren, Yuping Wang, Qinghong Guo, Rui Ji, Yongning Zhou\",\"doi\":\"10.1007/s10120-025-01644-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>TFF2 is a promising yet underexplored biomarker for gastric cancer. We aimed to investigate the relationship between serum TFF2 and gastric cancer, including early gastric cancer, and its interactions with other factors.</p><p><strong>Methods: </strong>A cross-sectional, population-based study was conducted involving 3986 participants from Wuwei Cohort. The serum levels of TFF2, TFF1, TFF3, PG I, PG II, and Hp IgG were measured. Logistic regression and restricted cubic splines assessed associations and dose-response relationships.</p><p><strong>Results: </strong>Gastric cancer prevalence rose across serum TFF2 tertiles, from 1.6 to 5.0% (p for trend < 0.001). TFF2 demonstrated the strongest association with gastric cancer, with participants in the highest tertile showing over a fourfold increased risk (OR 4.02, 95% CI 2.25-7.19, p < 0.001) after adjusting for traditional risk factors and other biomarkers. The association remained robust for early gastric cancer, exhibiting over a threefold risk (OR 3.31, 95% CI 1.80-6.08, p < 0.001). RCS analyses confirmed dose-response relationships (p for non-linearity < 0.05). The joint analyses showed that participants in the highest tertiles of both TFF1 and TFF2, or in the lowest tertile of TFF1 and highest tertile of TFF2, had at least an eightfold increased risk of gastric cancer and early gastric cancer compared to those with both biomarkers in the lowest tertile.</p><p><strong>Conclusion: </strong>Serum TFF2 is a more reliable biomarker for gastric cancer, including early gastric cancer, in the general population. Its strong dose-response association with gastric cancer outcomes and the synergistic effects with TFF1 highlight its potential to improve risk prediction and guide future research.</p>\",\"PeriodicalId\":12684,\"journal\":{\"name\":\"Gastric Cancer\",\"volume\":\" \",\"pages\":\"852-861\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastric Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10120-025-01644-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastric Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10120-025-01644-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study.
Background: TFF2 is a promising yet underexplored biomarker for gastric cancer. We aimed to investigate the relationship between serum TFF2 and gastric cancer, including early gastric cancer, and its interactions with other factors.
Methods: A cross-sectional, population-based study was conducted involving 3986 participants from Wuwei Cohort. The serum levels of TFF2, TFF1, TFF3, PG I, PG II, and Hp IgG were measured. Logistic regression and restricted cubic splines assessed associations and dose-response relationships.
Results: Gastric cancer prevalence rose across serum TFF2 tertiles, from 1.6 to 5.0% (p for trend < 0.001). TFF2 demonstrated the strongest association with gastric cancer, with participants in the highest tertile showing over a fourfold increased risk (OR 4.02, 95% CI 2.25-7.19, p < 0.001) after adjusting for traditional risk factors and other biomarkers. The association remained robust for early gastric cancer, exhibiting over a threefold risk (OR 3.31, 95% CI 1.80-6.08, p < 0.001). RCS analyses confirmed dose-response relationships (p for non-linearity < 0.05). The joint analyses showed that participants in the highest tertiles of both TFF1 and TFF2, or in the lowest tertile of TFF1 and highest tertile of TFF2, had at least an eightfold increased risk of gastric cancer and early gastric cancer compared to those with both biomarkers in the lowest tertile.
Conclusion: Serum TFF2 is a more reliable biomarker for gastric cancer, including early gastric cancer, in the general population. Its strong dose-response association with gastric cancer outcomes and the synergistic effects with TFF1 highlight its potential to improve risk prediction and guide future research.
期刊介绍：
Gastric Cancer is an esteemed global forum that focuses on various aspects of gastric cancer research, treatment, and biology worldwide.
The journal promotes a diverse range of content, including original articles, case reports, short communications, and technical notes. It also welcomes Letters to the Editor discussing published articles or sharing viewpoints on gastric cancer topics.
Review articles are predominantly sought after by the Editor, ensuring comprehensive coverage of the field.
With a dedicated and knowledgeable editorial team, the journal is committed to providing exceptional support and ensuring high levels of author satisfaction. In fact, over 90% of published authors have expressed their intent to publish again in our esteemed journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
